AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9481724
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg folic acid daily for 40 weeks
Trial: 9481724
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg folic acid daily for four weeks
Trial: 8550857
Drug: MOTS CPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOTS CPC (6.6 mg cetylpyridinium chloride), 2 x daily for 2 hours intra-orally
Trial: 8550857
Drug: Peridex (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peridex (15 ml, 2 x daily for 30 seconds rinsing)
Trial: 2677961
Drug: Milk-based diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based diet containing 6 g/kg of body weight per day of lactose
Trial: 7857040
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no prophylactic antibiotics)
Trial: 7040157
Drug: Chlorpromazine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (1 mg/kg)
Trial: 7040157
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (hydration and tetracycline)
Trial: 24679880
Drug: Dissolution therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissolution therapy with potassium sodium hydrogen citrate at a dose of 1 mEq/kg per day for 1 to 3 months
Trial: 20491229
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser (GaAIAs ‐ 780 nm) applied on the temporalis and masseter muscles, energetic doses of 25 J/cm2 and 60 J/cm2, applied twice a week for four weeks
Trial: 11978902
Drug: Risedronate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate treatment for 3 years
Trial: 7642415
Drug: Alternating chemo-radiotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemo-radiotherapy (Cisplatin 20 mg/mq and Methotrexate 40 mg/mq instead of 5-Fluorouracil) with two cycles of 25 Gy/10 fractions/12 days each.
Trial: 26124031
Drug: Intrusive force
RxNorm normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrusive force of 250 g (heavy)
Trial: 21192139
Drug: Sertraline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (up to 200 mg daily)
Trial: 19581310
Drug: Concurrent three-dimensional
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent three-dimensional conformal radiotherapy (3D‐CRT) and androgen deprivation (AD)
Trial: 11535311
Drug: Chromatographically purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromatographically purified rabies vaccine (CPRV)
Trial: 11535311
Drug: Human diploid
RxNorm normalized name: rabies vaccine, human diploid cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human diploid cell vaccine (HDCV)
Trial: 2441535
Drug: sotalol (160‐320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sotalol (160‐320 mg p.o.) + mexiletine (600‐800 mg p.o.)
Trial: 22206748
Drug: Pulsatile infusion
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile infusion of oxytocin
Trial: 22206748
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of oxytocin
Trial: 18602511
Drug: 60 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 cc of gin (18.5 g of ethanol)
Trial: 18602511
Drug: 180 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 cc of red wine (18.9 g of ethanol)
Trial: 18602511
Drug: Placebo (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (120 cc of water)
Trial: 9274547
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (2 g/day of elemental calcium)
Trial: 1477851
Drug: Dextromethorphan (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (60 or 90 mg p.o. q.i.d.)
Trial: 26041041
Drug: Bivalent genogroup
RxNorm normalized name: Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent genogroup 1 genotype 1 (GI.1)/GII.4 norovirus vaccine
Trial: 11911356
Drug: Intragastric infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intragastric infusion of Lipofundin S 20% (306 kcal)
Trial: 7714309
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT); Components: cognitive restructuring and assertion training; Population size: 24
Trial: 29410318
Drug: 1% diacerein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% diacerein cream
Trial: 25713600
Drug: Donepezil 10
RxNorm normalized name: donepezil 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg
Trial: 20335632
Drug: Multi-micronutrient supplement
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-micronutrient supplement (daily dose containing vitamins A, B complex, C, D, E, folic acid, copper, iron, and zinc)
Trial: 19689077
Drug: Multi-micronutrient supplement
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-micronutrient supplement
Trial: 18242753
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (pelvic muscle exercises plus advice on healthy living)
Trial: 29389568
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of pearl powder/d (n=10)
Trial: 23299530
Drug: Cediranib 30
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 30 mg
Trial: 6179337
Drug: UVB exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB exposure 2-3 times weekly for 4 weeks
Trial: 6179337
Drug: UVA exposure
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA exposure 2-3 times weekly for 4 weeks
Trial: 6179337
Drug: PUVA exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA exposure 2-3 times weekly for 4 weeks
Trial: 16123958
Drug: Delayed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delayed low-dose tacrolimus (target trough level 4-8 ng/mL, starting day 4-6) with daclizumab and mycophenolate mofetil
Trial: 12069736
Drug: Buserelin 150
RxNorm normalized name: buserelin 150 MCG/ACTUAT Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin 150 microg nasal spray three times daily (Group B)
Trial: 12069736
Drug: Nafarelin nasal
RxNorm normalized name: nafarelin Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin nasal spray 400 microg twice daily (Group N)
Trial: 12069736
Drug: Leuprorelin depot
RxNorm normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L)
Trial: 3304348
Drug: Cefazolin sodium,
RxNorm normalized name: CeFAZolin Sodium, 1 g/10 mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin sodium, 1 g intravenously, one hour prior to surgery and a similar dose eight hours later
Trial: 24670351
Drug: Krka's formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krka's formulation of clopidogrel under fasting conditions
Trial: 24670351
Drug: Innovator's formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovator's formulation of clopidogrel under fed conditions
Trial: 24670351
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of clopidogrel
Trial: 11951812
Drug: Controlled-release alpha-lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release alpha-lipoic acid (CRLA) 900 mg daily for 6 weeks, then 1200 mg daily for an additional 6 weeks
Trial: 11951812
Drug: Controlled-release alpha-lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release alpha-lipoic acid (CRLA)
Trial: 10402336
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine 1 mg/kg
Trial: 8918852
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention addressing AAS effects, sports nutrition, strength-training alternatives, drug refusal role play, anti-AAS media messages, and weight-room sessions.
Trial: 9609217
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose heparin or warfarin
Trial: 503385
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) gel (0.5 mg PGE2) intracervically
Trial: 27180890
Drug: Macitentan 10
RxNorm normalized name: macitentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macitentan 10 mg once daily
Trial: 31900959
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg once daily
Trial: 17513655
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (lidocaine and remifentanil)
Trial: 22508772
Drug: apremilast 20
RxNorm normalized name: apremilast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apremilast 20 mg twice daily
Trial: 23485720
Drug: Lactulose therapy
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose therapy
Trial: 11422660
Drug: Control (NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (NaCl infusion)
Trial: 3027884
Drug: Tinidazole treatment
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole treatment for 5 days
Trial: 22615318
Drug: Tinidazole treatment
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole treatment
Trial: 31535332
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14)
Trial: 29889698
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (1 mg)
Trial: 8780333
Drug: Fluoxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (60 mg)
Trial: 2677125
Drug: lofepramine (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lofepramine (70 mg, 105 mg, 140 mg)
Trial: 699626
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg aspirin 4-times daily
Trial: 699626
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg aspirin 4-times daily
Trial: 30705241
Drug: Dysarthria therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysarthria therapy via Skype
Trial: 25176266
Drug: Intravenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous laser irradiation of blood (ILIB) with semiconductor laser (wavelength - 0.67 microns, power output - 3-2 mW) in addition to standard treatment
Trial: 25176266
Drug: Intravenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous laser irradiation of blood (ILIB) with semiconductor laser
Trial: 15059282
Drug: Prednisone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (2 mg/kg/day for one week, with weaning over a second week)
Trial: 11384567
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of pilocarpine and latanoprost
Trial: 11384567
Drug: Latanoprost (0.005%)
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost (0.005%) once daily to one eye and vehicle to the other
Trial: 30085184
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (DT) with a ritonavir‐boosted PI (PI/r) plus lamivudine
Trial: 30085184
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (TT) with PI/r plus two nucleos(t)ide reverse transcriptase inhibitors (N(t)RTIs)
Trial: 24865619
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management treatment
Trial: 16621194
Drug: Pentavalent vaccine
RxNorm normalized name: rotavirus, live, pentavalent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent vaccine (G1, G2, G3, G4, and P1A)
Trial: 16621194
Drug: Monovalent P1A
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent P1A vaccine
Trial: 11236243
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of G-CSF and CEA
Trial: 29505522
Drug: High tidal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tidal volume (VT ≥ 8 mL/kg) + pressure controlled ventilation (PCV)
Trial: 26811112
Drug: Preoperative hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative hemoglobin <13 g/dL
Trial: 21069899
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at an effect-site concentration of 2.0 ng/ml (RF₂(.)₀)
Trial: 21069899
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at an effect-site concentration of 2.5 ng/ml (RF₂(.)₅)
Trial: 6426073
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate 10 mg inhaled from a pressurised metered dose inhaler
Trial: 30990550
Drug: Doxepin mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin mouthwash (25 mg/5 mL water)
Trial: 17303494
Drug: Misoprostol 6-8
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 6-8 hours after mifepristone treatment
Trial: 17303494
Drug: Misoprostol 24
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 24 hours after mifepristone treatment
Trial: 19238647
Drug: 10% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% lidocaine spray plus 2% lidocaine jelly lubrication
Trial: 9011481
Drug: High-dose interferon-alpha2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon-alpha2b (10 MU administered subcutaneously daily until normalization of serum transaminase concentrations)
Trial: 9011481
Drug: High-dose interferon-alpha2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon-alpha2b
Trial: 31434028
Drug: Nicotine-containing e-cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine-containing e-cigarettes (6 mg/mL)
Trial: 24584988
Drug: Standard ACT
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ACT (N=85) - provided standard assertive community treatment
Trial: 22910929
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (CR and TT)
Trial: 20417565
Drug: Myoconjunctival PMMA
RxNorm normalized name: pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myoconjunctival PMMA implant
Trial: 20417565
Drug: Traditional PMMA
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional PMMA implant
Trial: 20417565
Drug: Porous polyethylene
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porous polyethylene implant
Trial: 18826868
Drug: Trileptal oral
RxNorm normalized name: Trileptal Oral Product
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trileptal oral suspension (300 mg)
Trial: 18826868
Drug: Film-coated tablet
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablet (300 mg)
Trial: 15915007
Drug: formoterol DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formoterol DPI (Aerolizer, 12-microg dose)
Trial: 10382128
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulfate and a 2-week course of bismuth subcitrate, amoxicillin, and metronidazole (Group A)
Trial: 10382128
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulfate and a 2-week course of placebo (Group C)
Trial: 9715289
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow oxygen (O2) inhalation
Trial: 2057244
Drug: EXOSURF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXOSURF (5 mL/kg intratracheally)
Trial: 2057244
Drug: Control (air
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (air 5 mL/kg intratracheally)
Trial: 30849345
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept monotherapy (IAI)
Trial: 30849345
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept plus rescue photodynamic therapy (IAI + rPDT)
Trial: 26011140
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care management (daily oral hydration and diclofenac 75 mg IM on demand)
Trial: 26011140
Drug: Alfuzosin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin therapy
Trial: 2764269
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch solution (HD-HES group, n = 15, ratio of replacement 1:1)
Trial: 29268598
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg)
Trial: 16489524
Drug: Sham laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham laser treatment (placebo)
Trial: 25542604
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser treatment
Trial: 12800795
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery followed by immunotherapy
Trial: 8468720
Drug: High-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interleukin-2 plus lymphokine-activated killer (LAK) cells
Trial: 8468720
Drug: High-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interleukin-2 alone
Trial: 8468720
Drug: High-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interleukin-2 plus LAK cells
Trial: 8468720
Drug: High-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interleukin-2 plus LAK cells (melanoma subgroup)
Trial: 8468720
Drug: High-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interleukin-2 alone (melanoma subgroup)
Trial: 25416075
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNS)
Trial: 15688235
Drug: Polidocanol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polidocanol (5 mg/ml)
Trial: 7784025
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot 7.5 mg
Trial: 2327885
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hospital-supervised bicycling with home walking
Trial: 30273493
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation (2 × 200 mg/day for 8 weeks)